Journal of Clinical Endocrinology & Metabolism, Vol 79, 1595-1599, Copyright © 1994 by Endocrine Society

ARTICLES

Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis

IR Reid, DJ Wattie, MC Evans, GD Gamble, JP Stapleton and J Cornish
Department of Medicine, University of Auckland, New Zealand.

There is a need for effective and acceptable therapies for postmenopausal osteoporosis. The bisphosphonates show promise in this role, but the effects of the potent bisphosphonates in established osteoporosis have not yet been reported. We performed a 2-yr, randomized, double blind, placebo-controlled trial of pamidronate (150 mg/day) in 48 postmenopausal osteoporotic women. Bone mineral density of the total body, lumbar spine, and proximal femur was measured every 6 months by dual energy x-ray absorptiometry. Bone mineral density increased progressively in the total body (1.9 +/- 0.7%; P < 0.01), lumbar spine (7.0 +/- 1.0%; P < 0.0001), and femoral trochanter (5.4 +/- 1.3%; P < 0.001) in subjects receiving pamidronate, but did not change significantly in those receiving placebo. There were significant decreases in bone density at both the femoral neck (P < 0.02) and Ward's triangle (P < 0.01) in subjects taking placebo, which did not occur in the pamidronate group. The differences between the treatment groups were significant at all sites (0.0001 < P < 0.05) except Ward's triangle. Vertebral fracture rates were 13/100 patient yr in the pamidronate group and 24/100 patient yr in those receiving placebo (P = 0.07), and there was a nonsignificant trend toward height loss being less in those receiving pamidronate (P = 0.16). It is concluded that pamidronate is an effective therapy in postmenopausal osteoporosis.

This article has been cited by other articles:

				C. MacLean, S. Newberry, M. Maglione, M. McMahon, V. Ranganath, M. Suttorp, W. Mojica, M. Timmer, A. Alexander, M. McNamara, et al. Systematic Review: Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis Ann Intern Med, February 5, 2008; 148(3): 197 - 213. [Abstract] [Full Text] [PDF]

				C. R. Parker, P. J. Blackwell, K. J. Fairbairn, and D. J. Hosking Alendronate in the Treatment of Primary Hyperparathyroid-Related Osteoporosis: A 2-Year Study J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4482 - 4489. [Abstract] [Full Text] [PDF]

				I. R. Reid, J. P. Brown, P. Burckhardt, Z. Horowitz, P. Richardson, U. Trechsel, A. Widmer, J.-P. Devogelaer, J.-M. Kaufman, P. Jaeger, et al. Intravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral Density N. Engl. J. Med., February 28, 2002; 346(9): 653 - 661. [Abstract] [Full Text] [PDF]

				J. Pfeilschifter and I. J. Diel Osteoporosis Due to Cancer Treatment: Pathogenesis and Management J. Clin. Oncol., April 7, 2000; 18(7): 1570 - 1593. [Abstract] [Full Text] [PDF]

				H. N. Rosen, A. C. Moses, J. Garber, D. S. Ross, S. L. Lee, L. Ferguson, V. Chen, K. Lee, and S. L. Greenspan Randomized Trial of Pamidronate in Patients with Thyroid Cancer: Bone Density Is Not Reduced by Suppressive Doses of Thyroxine, But Is Increased by Cyclic Intravenous Pamidronate J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2324 - 2330. [Abstract] [Full Text]

				H. Fleisch Bisphosphonates: Mechanisms of Action Endocr. Rev., February 1, 1998; 19(1): 80 - 100. [Abstract] [Full Text]